New therapeutic target for the non-electrophysiological signaling in atrial fibrosis and fibrillation such as inflammation

Journal of Arrhythmia

Volumn 28, Issue 3, 2012, Pages 145-154

  Takahashi, Naohiko ^a   Kume, Osamu ^a   Wakisaka, Osamu ^a   Teshima, Yasushi ^a   Hara, Masahide ^a   Saikawa, Tetsunori ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Atrial fibrosis; Gap junction; Heat shock protein; Inflammation

Indexed keywords

EID: 84867861506     PISSN: 18804276     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joa.2012.05.001     Document Type: Review

References (53)

1. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (atria) study. JAMA 2001;285:2370-5.
3. Naccarelli GV, Gonzalez MD. Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future? J Cardiovasc Pharmacol 2008;52:203-9.
4. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51:802-9.
5. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
6. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204.
7. Wakisaka O, Takahashi N, Shinohara T, et al. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72. J Mol Cell Cardiol 2007;43:616-26.
8. Kume O, Takahashi N, Wakisaka O, et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011;8:278-85.
9. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: Primary Prev Europace 2011;13:308-28.
10. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: Secondary Prev Europace 2011;13:610-25.
11. Iwasaki YK, Nishida K, Kato T, et al. Atrial fibrillation pathophysiology: implications for management. Circulation 2011;124:2264-74.
12. Benjamin IJ, McMillan DR. Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease. Circ Res 1998;83:117-32.
13. Ooie T, Takahashi N, Saikawa T, et al. Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 2001;104:1837-43.
14. Mandal K, Torsney E, Poloniecki J, et al. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann Thorac Surg 2005;79:865-71.
15. Brundel BJ, Henning RH, Ke L, et al. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol 2006;41:555-62.
16. Brundel BJ, Shiroshita-Takeshita A, Qi X, et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 2006;99:1394-402.
17. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995;98:476-84.
18. Sinno H, Derakhchan K, Libersan D., et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003;107:1930-1936.
19. Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res 2008;78:63-70.
20. Yamanaka K, Takahashi N, Ooie T, et al. Role of protein kinase C in geranylgeranylacetone-induced expression of heat-shock protein 72 and cardioprotection in the rat heart. J Mol Cell Cardiol 2003;35:785-94.
21. Shinohara T, Takahashi N, Ooie T, et al. Phosphatidylinositol 3-kinasedependent activation of akt, an essential signal for hyperthermia-induced heat-shock protein 72, is attenuated in streptozotocin-induced diabetic heart. Diabetes 2006;55:1307-15.
22. Taniguchi Y, Takahashi N, Fukui A, et al. Candesartan restored cardiac Hsp72 expression and tolerance against reperfusion injury in hereditary insulinresistant rats. Cardiovasc Res 2011;92:439-48.
23. Takahashi N, Wakisaka O, Yoshimatsu H, et al. Induction of heat shock proteins prevents the arrhythmogenic substrate for atrial fibrillation. Int J Hyperthermia 2009;25:641-6.
24. Hu YF, Yeh HI, Tsao HM, et al. Electrophysiological Correlation and Prognostic Impact of Heat Shock Protein 27 in Atrial Fibrillation. Circ Arrhythm Electrophysiol. [Epub ahead of print].
25. Gehrig SM, Van Der Poel C, Sayer TA, et al. Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 2012;484:394-8.
26. 2+ model: sinus rhythm and chronic atrial fibrillation. Circ Res 2011;109:1055-66.
27. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008;24:14-26.
28. Nakamoto M, Ohya Y, Shinzato T, et al. Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in saltsensitive hypertension. Hypertens Res 2008;31:353-61.
29. Kato MF, Shibata R, Obata K, et al. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens 2008;26:1669-76.
30. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferatoractivated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008;5:451-9.
31. Libby P, Ridker PM, Hansson GK. Leducq Transatlantic network on atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
32. Yamashita T, Sekiguchi A, Iwasaki YK, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010;74:262-70.
33. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-66.
34. Kasai T, Miyauchi K, Yokoyama T, et al. Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis 2008;197:612-9.
35. Kai H, Kuwahara F, Tokuda K, et al. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005;28:483-90.
36. Xia Y, Lee K, Li N, et al. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol 2009;131:471-81.
37. Li J, Solus J, Chen Q, Rho YH, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010;7:438-44.
38. Xu D, Murakoshi N, Igarashi M, et al. PPAR-g activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J Cardiovasc Electrophysiol 2012;23:209-17.
39. Gu J, Liu X, Wang X, Shi H, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011;13:1256-61.
40. Wetzel U, Boldt A, Lauschke J, et al. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart 2005;91:166-70.
41. Chaldoupi SM, Loh P, Hauer RN, et al. The role of connexin40 in atrial fibrillation. Cardiovasc Res 2009;84:15-23.
42. Yang YQ, Zhang XL, Wang XH, et al. Connexin40 nonsense mutation in familial atrial fibrillation. Int J Mol Med 2010;26:605-10.
43. Bikou O, Thomas D, Trappe K, et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 2011;92:218-25.
44. Kim SJ, Choisy SC, Barman P, et al. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. Circ Arrhythm Electrophysiol 2011;4:761-9.
45. Polontchouk L, Haefliger JA, Ebelt B, et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001;38:883-91.
46. Van Der Velden HM, Ausma J, et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000;46:476-86.
47. Emdad L, Uzzaman M, Takagishi Y, et al. Gap junction remodeling in hypertrophied left ventricles of aortic-banded rats: prevention by angiotensin II type 1 receptor blockade. J Mol Cell Cardiol 2001;33:219-31.
48. Rucker-Martin C, Milliez P, Tan S, et al. Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res 2006;72:69-79.
49. Polontchouk L, Ebelt B, Jackels M, et al. Chronic effects of endothelin 1 and angiotensin II on gap junctions and intercellular communication in cardiac cells. FASEB J 2002;16:87-9.
50. Shyu KG, Chen CC, Wang BW, et al. Angiotensin II receptor antagonist blocks the expression of connexin43 induced by cyclical mechanical stretch in cultured neonatal rat cardiac myocytes. Mol Cell Cardiol 2001;33:691-8.
51. Inoue N, Ohkusa T, Nao T, et al. Rapid electrical stimulation of contraction modulates gap junction protein in neonatal rat cultured cardiomyocytes: involvement of mitogen-activated protein kinases and effects of angiotensin II-receptor antagonist. J Am Coll Cardiol 2004;44:914-22.
52. Giepmans BN. Gap junctions and connexin-interacting proteins. Cardiovasc Res 2004;62:233-45.
53. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17.